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Abstract: The impact of high-density lipoprotein (HDL) cholesterol on the development of
atherosclerosis and diseases of systemic circulation has been well documented both in experimental and
registry studies. Recent discoveries in pulmonary arterial hypertension (PAH) revealed a significant
impact of HDL on pulmonary artery vasoreactivity and patients’ prognosis. The vasoprotective
activity of HDL primarily involves vascular endothelium that also plays a central role in pulmonary
arterial hypertension (PAH) pathobiology. However, the exact mechanism in which this lipoprotein
fraction exerts its effect in pulmonary circulation is still under investigation. This paper reviews
potential vasoprotective mechanisms of HDL in pulmonary circulation and presents current clinical
reports on the role of HDL in PAH patients.
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1. Protective Role of HDL in the Systemic Circulation
The significance of plasma high-density lipoprotein (HDL) cholesterol concentration in the
development and progression of diseases has been documented by reports from both experimental
and observational studies. The strong inverse relationship between HDL and cardiovascular disease
was first established by the Framingham Heart Study [1]. This observation led to the hypothesis that
HDL cholesterol might demonstrate protective properties against coronary artery disease. Further,
it was supported by a series of animal studies showing inhibition of atherosclerosis in cholesterol-fed
rabbits after HDL infusion [2] and in transgenic mice overexpressing apolipoprotein A-I (apoA-I) [3],
which is the major protein component of HDL particles. A number of prospective studies in
different populations have confirmed a strong and independent role of decreased HDL in the
prediction of adverse cardiovascular events in the secondary prevention settings [4,5]. Despite the
fact that low plasma levels of HDL are closely associated with increased risk of cardiovascular events,
elevated HDL does not always provide clear protection against atherosclerosis. The challenges to
the HDL hypothesis of cardiovascular diseases are also driven by studies in patients with Mendelian
disorders of lipoprotein metabolism. Mutations in apoA-I, ATP-binding cassette transporter A1 and
lecithin:cholesterol acyltransferase can lead to extremely low HDL levels but usually without advanced
coronary artery disease [6–9]. Conversely, deficiency in cholesteryl ester transfer protein (CETP)
activity resulting in increased HDL levels does not unequivocally protect against atherosclerosis [10].
Similarly, mutations resulting in structural alterations of apoA-I (e.g., Milano variant) are associated
with decreased HDL concentration but not with coronary artery disease [11]. In addition to the
abovementioned studies, several randomized studies aiming to improve HDL concentration failed to
improve patients’ outcomes in the current statin era. Despite the previous reports suggesting benefits
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of increasing HDL concentration with nicotinic acid [12], current trials with extended-release niacin as
an add-on therapy to the background statin failed to reduce the risk of cardiovascular events [13,14].
Previous trials with CETP inhibitors: Torcetrapib and dalcetrapib failed to show the beneficial effect of
increasing HDL on cardiovascular risk [15,16]. Following studies investigating new CETP inhibitors
showed equivocal results. While the use of anacetrapib decreased the risk of major cardiovascular
events [17], treatment with evacetrapib did not provide similar benefits in high-risk patients [18].
The recent meta-analysis with the Mendelian randomization approach also showed that increased
HDL associated with CETP gene polymorphism cannot be translated into reduction of cardiovascular
risk [19]. What is more, in the dal-ACUTE study with dalcetrapib, authors have shown the dissociation
between an increase of HDL levels and improvements in HDL function [20]. This highlighted the
importance of HDL function in cardiovascular protection, which cannot be accurately estimated only
by measuring lipoprotein concentration [21,22].
2. Pulmonary Arterial Hypertension
Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure
≥25 mmHg at rest as measured in right heart catheterization. Pulmonary arterial hypertension
(PAH) describes a subject with pre-capillary PH (pulmonary artery wedge pressure ≤15 mmHg
and a pulmonary vascular resistance >3 Wood units) in the absence of conditions such as PH
due to lung diseases, chronic thromboembolic pulmonary hypertension, or other rare diseases [23].
PAH is a severe and progressive disease in which pulmonary vascular cells undergo uncontrolled
hyperplasia leading to the narrowing and obliteration of small pulmonary arteries. Due to endothelial
dysfunction, endogenous production of pulmonary vasodilators, including nitric oxide and prostanoids,
is downregulated while increased levels of vasoconstrictors, including endothelin-1, contribute to
vascular remodeling. This results in an increase of pulmonary vascular resistance, elevation of
pulmonary artery pressure, and eventually heart failure [24,25]. PAH may be associated with different
medical conditions, including HIV, connective tissue disease, heart defects, drug and stimulant
intake and portal hypertension. In patients without any known predisposing factors or positive
family history, idiopathic PAH (IPAH) can be diagnosed [23]. The first symptoms of PAH are mostly
related to right ventricular dysfunction and are typically present during exertion. Most common
symptoms of PAH include progressive shortness of breath, weakness, fatigue, angina, and syncope.
The first line evaluation usually includes echocardiography, which can reveal the effects of PAH
on the heart. This, however, always requires complementary non-invasive diagnostics and cardiac
catheterization to establish the final diagnosis and support a treatment decision [23]. Currently available
PAH-specific therapies are directed towards known pathomechanisms leading to pulmonary vascular
disease and include calcium channel blockers, endothelin receptor antagonists, phosphodiesterase
type 5 inhibitors, guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin receptor
agonists. While the contemporary survival of PAH patients is constantly improving due to the latest
development of PAH-specific therapies, this condition is still considered as incurable [26]. To optimize
patients’ care, a comprehensive assessment of treated patients is regularly performed in the reference
centers. Ongoing clinical trials and large PAH registries including REVEAL [27], COMPERA [28],
SPAHR [29], French registry [30], and many others enabled the formation and validation risk assessment
tools incorporating multiple clinical (signs and symptoms of right heart failure, WHO functional
class, six-minute walk distance, cardiopulmonary exercise testing), laboratory (N-terminal pro-brain
natriuretic peptide concentration), imaging (right atrial area, presence of pericardial effusion in
echocardiography, or cardiac magnetic resonance), and hemodynamic parameters (right atrial pressure,
cardiac index, and mixed venous oxygen saturation), since there is no single variable that provides
sufficient prognostic information. Based on the abovementioned parameters, the European PH
guidelines formed a risk assessment tool widely used to stratify patients into low, intermediate,
or high-risk groups according to estimated one-year mortality [23]. Classification and characteristics of
different types of PH are presented in detail in Table 1.
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3. HDL-Mediated Mechanisms of Cardiovascular Protection in Pulmonary Hypertension
Recently, PAH has been considered as a systemic disease due to the involvement of numerous
organs and tissues and metabolic and inflammatory abnormalities [31–33]. Its etiology still remains
unclear; however, recent studies revealed a significant role of endothelial dysfunction, inflammation,
and altered metabolism in an onset and progression of the disease. Decreased HDL level and insulin
resistance defined as increased triglyceride to HDL ratio was found to be more prevalent in the PAH
population than in age-matched controls [34–36]. This was also associated with poor survival [34,37]
and more advanced pulmonary vascular disease [38]. Vasoprotective properties of HDL primarily
involve vascular endothelium that also plays a central role in PAH pathobiology. Traditionally,
HDL capability to prevent atherosclerosis in the systemic circulation is explained by reverse cholesterol
transport (RCT) allowing a transfer of cholesterol from the arterial wall to the liver [39,40]. A growing
body of evidence indicates, however, a significant role of functions other than RCT vasoprotective
functions of HDL that may play an important role in pulmonary circulation. Potential mechanisms of
HDL-dependent vascular protection are summarized in Table 2.
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Table 2. Potential mechanisms of vascular protection in pulmonary circulation.
Biological Activity of HDL Potential Mechanisms of Vascular Protection
Vasodilatory activity
• Stimulation of NO production
• Prostacyclin release
• Decreased production of reactive oxygen species
Anti-inflammatory properties
• Downregulation of adhesion molecule
• Inhibition of monocyte activation
• Downregulation of proinflammatory macrophages
• Inhibition of NFkB and TNF-alpha signaling in
endothelial cells
Antioxidative properties
• Protection of LDL from oxidation
• Inhibition of cellular superoxide production
Cytoprotection
• Protection of endothelial cells from apoptosis
• Modulation of mitochondrial electron transport
• Reduced cellular superoxide production
• Antiapoptotic signaling via ABCG1
• Protection from extracellular matrix degradation by
serpin peptidase inhibitors
Modulation of glucose metabolism
• Stimulation of pancreatic insulin secretion
• Decrease of insulin resistance
• Modulation of cholesterol homeostasis
• Modulation of adipocyte metabolism
Regulation of platelet activation
• Inhibition of platelet aggregation
• Anti-thrombotic effects on endothelium
• Upregulation of NO production
• Inhibition of calcium release
Regulation of gene expression • Transport of small non-coding microRNA
ABCG1—ATP-binding cassette sub-family G member 1, NFkB—nuclear factor kappa-light-chain-enhancer of
activated B cells, NO—nitric oxide, TNF-α—tumor necrosis factor α.
4. HDL in NO and Prostacyclin Pathway
The molecular mechanism explaining the role of HDL in maintaining optimal pulmonary
vascular resistance was identified as vasodilation via endothelial nitric oxide (NO) and
prostacyclin release. Worth mentioning is the fact that most of the currently used PAH-specific
medications, including phosphodiesterase 5 inhibitors, direct stimulators of soluble guanylate
cyclase, and prostacyclin analogues, act on vascular endothelium by enhancing NO and prostacyclin
signaling [41,42]. In the study by Nofer et al., HDL was shown to stimulate NO release from
human endothelial cells and promote vasodilation in isolated aorta. These effects were ascribed to
three lysophospholipids present in HDL: Sphingosylphosphorylcholine, sphingosine-1-phosphate,
and lysosulfatide. All mentioned were able to elevate intracellular Ca2+ concentration, resulting in
NO release and vascular relaxation. What is more, deficiency of the lysophospholipid receptor S1P3
decreased these vasodilatory effects of HDL by 60% [41]. Another study by Yuhanna et al. showed
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that endothelial NO synthase (eNOS) is stimulated by HDL in cultured endothelial cells but not by
LDL cholesterol. Further expression experiments in animal models revealed that HDL signaling is
mediated by scavenger receptor-BI (SR-BI), and subsequent phosphorylation of eNOS. HDL activation
of eNOS was demonstrated in endothelial cell caveolae where both SR-BI and eNOS are localized.
The addition of SR-BI and apo-AI antibodies was able to inhibit the response of isolated plasma
membranes. HDL was also able to enhance nitric-oxide-dependent vascular relaxation in aorta of
wild-type mice, but not in vessels from mice with homozygous null SR-BI knockout. This indicates
that HDL can activate eNOS via SR-BI through a process that requires apoA-I binding [43]. This was
further confirmed by extended study examining the molecular mechanism responsible for the increase
in nitric oxide production. The HDL/SR-BI-dependent stimulation of eNOS was mediated mainly
by an increase in intracellular ceramide levels independent of an increase in intracellular calcium
or Akt kinase phosphorylation [44]. Another HDL-dependent pathway leading to vasodilatation is
mediated by ATP-binding cassette G1 (ABCG1), which is a member of the large family of lipid, drug,
and metabolite transporters. The ABCG1 role was initially associated with mediating cholesterol
efflux from macrophages and maintaining tissue lipid homeostasis. Recently, the role of ABCG1 was
established in modulation of different aspects of glucose and lipid metabolism. By controlling secretion
and activity of lipoprotein lipase and insulin, ABCG1 can impact the risk of cardiovascular diseases,
including pulmonary circulation. Worth mentioning is the fact that most of the data on vasodilatatory
functions of HDL are derived from animal models of systemic circulation [45]. Previous studies on
peripheral artery reactivity in subjects with intermediate and high cardiovascular risk confirmed a
strong association between both HDL cholesterol and apo-AI concentrations, and vasoreactivity of
small resistance arteries [46].
5. HDL and Inflammation
HDL also displays potent anti-inflammatory properties. It is worth noticing that, in animal
models of PAH, both inflammation and altered immunity induce vascular remodeling. Importantly,
it was shown that both pulmonary vascular cells and inflammatory cells can be an important source of
inflammatory cytokines that lead to vascular contractility, proliferation, and remodeling typical for
PAH. As recently shown, interleukin(IL)-1 can induce fibroblast growth factor 2 and, together with
IL-6, plays a central role in promoting the proliferation of fibroblasts and smooth muscle cells of the
pulmonary vasculature in PAH [47]. HDL particles and reconstituted HDL are effective inhibitors of
cytokine-induced expression of vascular and intercellular adhesion molecules. The endothelial cell
expression of these molecules has been further implicated in the recruitment of monocytes and the
development of cardiovascular disease in in-vivo and in-vitro models [48]. T-lymphocytes may exert
an inflammatory effect through significant up-regulation of IL-1β, tumor necrosis factor-α (TNF-α),
and nuclear factor kappa-light-chain-enhancer of activated B cells signaling. This mechanism is likely
to be involved in the pathogenesis of chronic inflammatory disorders leading to tissue destruction
and development of pulmonary vascular disease. HDL by interacting with T-lymphocytes can inhibit
monocyte stimulation and production of inflammatory cytokines. This anti-inflammatory function of
HDL is attributed mainly to their main protein component, apoA–I, which binds activating factors at
the surface of stimulated T cells [49]. HDL was also able to suppress interferon gamma production in
human macrophages [50] and to induce macrophage transcriptional regulator ATF3, which resulted in
toll-like receptor-dependent attenuation of inflammation [51].
This represents a potent mechanism in which HDL can modulate both innate and adaptive
immunity and therefore prevent pulmonary vascular remodeling. What is more, HDL can bind
circulating lipopolysaccharides (LPS), facilitate its hepatic clearance, and prevent LPS-induced
endotoxemia. HDL also exhibits a potent impact on monocyte differentiation and IL-1β secretion in
response to LPS in metabolic syndrome patients [52]. The vasoprotective and anti-inflammatory role
of HDL was recently attributed to its bioactive components, including sphingosine 1-phosphate (S1P),
which can regulate vascular functions and modulate immunity. S1P vascular signaling can be mediated
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by different G-protein-coupled receptors (S1P1–S1P5) resulting in contradictory effects on vascular
remodeling. Some studies documented that S1P can induce vasoconstriction and development of
pulmonary vascular disease via S1P2 receptors [53]. The other showed that stimulation of endothelial
S1P1 receptor with HDL-bound S1P was able to mitigate inflammation in both in-vitro and in-vivo
models by downregulation of adhesion molecules. Interestingly, albumin-bound S1P failed to exert a
similar anti-inflammatory effect [54].
HDL-mediated anti-inflammatory properties are also closely associated with HDL’s ability to
protect LDL and other lipoproteins from free radical-induced oxidative damage. Selective increase
of HDL particles displaying decreased surface rigidity and rich in apoA-I were able to attenuate
oxidative damage and mitigate inflammation. The antioxidant pathway includes a transfer of altered
lipids from LDL to HDL particles and subsequent reduction of oxidized lipids by apoA-I and other
HDL components [55]. These position the HDL particle as a major transport vehicle and redox-active
component able to prevent vascular cell injury [56]. The antioxidant and anti-inflammatory role of
HDL was recently confirmed also in subjects with PAH. Markers of oxidant stress may potentially
contribute to the pathogenesis of PAH by inhibiting endothelial prostacyclin release, which plays
a central role in pulmonary circulation. Ross et al. described proinflammatory HDL dysfunction
not only in patients with connective tissue disease-associated PAH but also in the IPAH cohort.
A significant increase in plasma levels of oxidation products of arachidonic and linoleic acid suggests
an oxidant stress contribution to the proinflammatory HDL dysfunction in this disease. Interestingly,
the HDL proinflammatory effects were mitigated by the treatment with an apoA-I mimetic peptide 4F,
which may represent a novel potential PAH therapeutic target [57]. Worth mentioning is HDL’s ability
to protect endothelial cells and macrophages from apoptosis. The preincubation of human endothelial
cells with HDL before incubation with TNF-α was able to prevent apoptosis in a dose-dependent
manner [58]. Other studies documented HDL-dependent cell protection from deleterious factors,
including cholesterol loading, activation of complement system, and withdrawal of growth factor [40].
6. HDL and Insulin Resistance
In the last years, impaired glucose and insulin metabolism was proposed as a novel risk factor in
pathobiology of PAH [34,37]. Recent studies in PAH patients reported a specific pattern of metabolic
alterations, including insulin resistance defined as elevated triglyceride to HDL cholesterol ratio [34,59],
glucose intolerance, and a blunted insulin response to an oral glucose load [60]. The exact link between
altered glucose metabolism and smooth muscle cell proliferation in pulmonary vascular disease is
still under investigation. A study comparing pulmonary artery smooth muscle cells (PASMCs) of
IPAH patients and controls identified increased activation of the hexosamine biosynthetic pathway
resulting in upregulated glycosylation and proliferation of PASMCs, leading to development of typical
vascular hallmarks of PAH. What is more, a partial knockdown of this metabolic pathway in PASMCs
of IPAH patients resulted in reduced PASMC proliferation. Finally, levels of glycosylation products
were associated with a risk of clinical worsening, including hospitalization, lung transplantation,
and all-cause mortality [61]. There is also strong evidence that HDL can improve glucose metabolism
and insulin sensitivity in skeletal muscles and adipocytes. Low levels of HDL can predict development
of type 2 diabetes mellitus and some medications used to raise HDL stimulate glucose metabolism
and prevent diabetes mellitus [62,63]. Infusion of reconstituted HDL in patients with type 2 diabetes
mellitus increased glucose disposal via mechanisms including increasing plasma insulin and activating
AMP-activated protein kinase in skeletal muscle [63]. The relationship between HDL and glucose
homeostasis is mediated by several different mechanisms, including HDL’s ability to stimulate insulin
secretion by pancreatic beta cells, improving insulin resistance, and regulating lipid metabolism [40].
7. HDL and Platelet Activation
Platelet activation is another phenomenon associated with numerous mechanisms observed in
the development of pulmonary vascular disease. Thrombotic lesions have been indicated as common
Int. J. Mol. Sci. 2019, 20, 3514 7 of 14
pathological findings in patients with PAH [64]. Arteriopathy of the small pulmonary vessels with
prominent thromboembolic changes was found in previous autopsy studies in PAH patients and
was considered an important pathogenetic factor in this disease [65]. In physiological conditions,
endothelial cells inhibit platelet aggregation by releasing nitric oxide and prostacyclin. This mitigates
thrombosis and promotes fibrinolytic cascade by stimulation of the tissue plasminogen activator.
In the case of pulmonary vascular injury, the platelet aggregation is accompanied by the release of
vasoconstrictive and proinflammatiory factors. What is more, platelet’s granules themselves are a
source of vasoactive molecules such as serotonin and tromboxane, growth factors, and proinflammatory
cytokines such as soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK), IL-1 β,
transforming growth factor β, and TNF-α [65], all of which are proposed to play a role in the
development of PAH. HDL exerts multiple anti-thrombotic properties by modulating increased
platelet activity in patients with metabolic syndrome and diabetes. This platelet hyperreactivity,
resulting in increased expression of surface receptors and adhesion molecules, enhanced production of
thrombin and thromboxane A2, and dysregulated platelet calcium homeostasis, was reversed in vitro
and in patients infused with reconstituted HDL. This effect was mainly attributed to reduction of
cholesterol content of platelet membranes and lipid raft disruption [66]. Antiplatelet activity of HDL
also includes interaction with platelet SR-BI, which in consequence leads to activation of protein kinase
C, inhibition of calcium release, and upregulation of NO cellular production [67]. Finally, HDL is
able to modulate pathways associated with PAH not only by stimulating NO synthesis but also by
inhibiting platelet aggregation and plasma coagulation factors [66,68].
8. HDL and microRNA
Recent studies indicate that HDL particles can regulate gene expression by binding and transporting
endogenous microRNA (miRNAs). miRNAs are involved in multiple cellular processes, including cell
differentiation, proliferation, and apoptosis. An emerging body of evidence indicates a substantial role
of miRNA signaling in maintaining homeostasis of the pulmonary circulation. Altered signaling of
miRNA has been associated with the development of numerous PAH vascular hallmarks. These include
endothelial dysfunction, smooth muscle cells proliferation, activation of fibroblasts, and formation of
plexiform lesions [69]. The bone morphogenetic protein receptor type II (BMPR2) signaling plays an
essential role in pulmonary circulation and BMPR2 mutations are the most common genetic cause
of PAH [70–72]. Potential interaction between BMPR2 expression and HDL in PAH is shown in
Figure 1. While dysfunction in BMPR2 signaling is unequivocally associated with pathogenesis of
PAH, the exact molecular mechanisms involved in this pathway are still under investigation [73].
The latest reports revealed involvement of miRNA-BMPR2 axis in PAH pathogenesis. Activation of
signal transducer and activator of transcription 3 by IL-6 was shown to induce the expression of the
miR-17-92 cluster in pulmonary artery endothelial cells. Interestingly, miR-17-5p and miR-20a encoded
in this cluster can target BMPR2 and, in consequence, downregulate expression of its protein [69]. It is,
however, important to underline that cell-to-cell communication mediated by miRNA may be difficult
because circulating miRNAs are quickly degraded. For that reason, most signaling miRNAs are
bound to protective proteins or microvesicles, such as exosomes [74]. Interestingly, recent biophysical
studies confirmed that extracellular miRNAs can bind to HDL through divalent cation bridging and
thus remain shielded from external RNases. Due to its high radius of curvature and lower surface
tension than other lipoproteins, HDL can facilitate binding a distinct pattern of miRNAs, which was
recently described by Vickers et al. [75]. The HDL-miRNA profile measured by the amplification-based
microarray platform was distinctly different from the exosome-derived profile. One of the most
abundant miRNAs transported by HDL, miR-223, was also shown to be downregulated in PASMCs
of PAH patients and has been associated with DNA damage in pulmonary artery smooth muscle
cells. Restoration of lung miR-223 signaling was able to reverse vascular remodeling typical for
PAH [76,77]. Until now, many clinical and experimental studies confirmed the association between
circulating miRNAs and disease progression in PAH. The exact role of the HDL-mediated miRNA
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delivery pathway requires further research, but its discovery opened the discussion on potential
miRNA-associated therapeutic targets in PAH [69,76,78].
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9. HDL and Pulmonary Vascular Disease Severity
The vasoprotective properties of HDL have been recently shown to play a significant role in
patients with different forms of PAH. Heresi et al. showed that PAH subjects are characterized with
lower HDL level than controls after adjusting for demographic factors and cardiovascular medical
history. Patients with higher HDL were also characterized by longer time to clinical worsening than
subjects with lower HDL values. What is more, in PAH patients, serum HDL concentration was
able to differentiate between survivors and non-survivors [79]. In another paper, Zhao et al. divided
76 idiopathic PAH patients into groups with high and low HDL levels. The subgroup did not differ
in terms of age, sex, or body mass index. Low HDL was associated with shorter six-minute walk
distance, lower cardiac index, lower mixed venous oxygen saturation, and higher pulmonary vascular
resistance. It was also established that serum HDL was an independent predictor of event-free survival
in the two-year follow-up [80]. These findings were, however, questioned by a report from the
French multicenter study of 110 PAH cases. The authors noted higher levels of HDL in PAH patients
than in previously mentioned reports and did not find an association between HDL and three-year
mortality [81]. Interestingly, in another large study by Larsen et al., in 227 PAH patients observed
for over five years it was confirmed that higher HDL levels were associated with significantly lower
mortality after adjusting for age, PAH therapy, and calculated disease-specific risk score [82]. To explain
the relationship between serum HDL levels and clinical outcomes in PAH patients, the investigators
from the Imperial College London analyzed metabolomics of two cohorts of patients with idiopathic
and heritable PAH. They explored lipoprotein profiles of 204 subjects by nuclear magnetic resonance
spectroscopy. They showed that downregulation of the smallest subclass of HDL (termed HDL-4) is
associated with increased risk of mortality. Interestingly, HDL-4 particles can transport proteins such as
prekallikrein, coagulation factor XI, and alpha-2-antiplasmin responsible for regulation of fibrinolysis,
a mechanism likely to contribute to the observed clinical outcomes [83,84]. Explaining the mechanism
in which lipoproteins can impact prognosis in debilitating and incurable disease seems promising in
the context of novel therapies. In our recent study of 66 idiopathic PAH patients, we showed that HDL
was able to predict pulmonary artery vasoreactivity and long-term response to calcium channel blocker
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therapy in patients with newly diagnosed disease. Additionally, we demonstrated that lower levels of
HDL-C are correlated with inflammatory cytokines; this indicates that chronic inflammation can mediate
the relationship between HDL-C and function of pulmonary vasculature [59,85]. The vasoprotective
role of HDL was also recently described in 90 patients with chronic thromboembolic pulmonary
hypertension (CTEPH). When compared to controls, CTEPH patients were characterized by lower
HDL cholesterol levels but higher when compared to the PAH population. In this group higher HDL
was associated with less prominent right ventricular dilation and a more favorable effect of pulmonary
thromboendarterectomy [86]. This suggests that HDL cholesterol may be a useful marker in pulmonary
vascular diseases of different origin.
10. Summary
Recent experimental and clinical data indicate protective properties of HDL in PAH, translating into
survival benefits in long-term observations. However, the exact mechanism in which this lipoprotein
fraction exerts its effect in pulmonary circulation is still under investigation and needs to be fully
explored before it can be translated to novel diagnostic and treatment methods [87,88].
Funding: This study was funded by Narodowe Centrum Nauki (grant no 2017/26/E/NZ5/01223).
Conflicts of Interest: The authors declare no conflict of interest.
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